{"id":935216,"date":"2026-02-09T08:49:36","date_gmt":"2026-02-09T13:49:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/"},"modified":"2026-02-09T08:49:36","modified_gmt":"2026-02-09T13:49:36","slug":"attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/","title":{"rendered":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA, Feb.  09, 2026  (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EXueOQp7V-oFZEfLbZZPuba2bQre1JBVmAkv98V16ALvsL2HCvp2Gl-U2269z3ZcoBN4WWOLKNZPFrH3dJkn3jIjGijTWIFNt0a-ihayPzc=\" rel=\"nofollow\" target=\"_blank\"><u>Berger Montague PC<\/u><\/a> announces that a class action lawsuit has been filed against <strong>Mereo BioPharma Group plc (NASDAQ: MREO)<\/strong> (\u201cMereo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from <strong>June 5, 2023 through December 26, 2025<\/strong> (the \u201cClass Period\u201d).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Investor Deadline:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Investors who purchased Mereo securities during the Class Period may, no later than <\/em><br \/>\n        <strong><br \/>\n          <em>\u00a0April 6, 2026<\/em><br \/>\n        <\/strong><br \/>\n        <em>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZKgA4a8CGGh-AP98G1WZ28t6AFB7U3VPAyE42RottwGja1ew4zSCaBvPUlKg9mqumW-1zNNsK1rQSpHdQbrg2khOjnSScJq2eVz-g6rjenYsULh9Q_6-8zX2fd4lNPtLnjtx3ZUBzS4cGVbhMRKJ1g==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>CLICK HERE<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <em>.<\/em>\n      <\/p>\n<p align=\"justify\">Headquartered in London, Mereo is a biopharmaceutical company specializing in treatments for rare diseases.<\/p>\n<p align=\"justify\">According to the complaint, while publicly raising investor expectations about the ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, Defendants misled investors by concealing that neither study significantly reduced the clinical fracture rates compared to control groups. Following the disclosure, Mereo\u2019s ADS price plummeted from a close of $2.31 on December 26, 2025 to a close of $0.29 per share on December 29,<strong> erasing more than 87.7% of its value in a single day<\/strong>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>If you are a Mereo investor and would like to learn more about this action, <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZKgA4a8CGGh-AP98G1WZ2zRvS6fHBkJj2aHV44CE3852P-MVvku4v0ZDH7c0Rj01Im8IQw9LFaooPksi_qWdDtp911-9xJcChNbx2QdkCKANWavkjMTW1SH9p-ndGMMgkBw8Zd-6ncyoPlDuRlJ0aw==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>CLICK HERE<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em>or please contact Berger Montague: Andrew Abramowitz at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iQESFsNz_ULb6g1S6rwtSlyw2hQLmkwKtElMB4J4vUTcCW23jyj1KXJjTI9PuwcIANiGoJVNTKUgZafUnCI9vornNJfhoo-_-ty220LWV91tY5kTs139Q12U5f5jL-rZ\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>aabramowitz@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (215) 875-3015, or Caitlin Adorni at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V8hascRkVOOpzZh1ZaJGR8-4NW9wsB1of1jTeJTgNcRyDFzxtmopvCEQIp2qfaVmy6XsolJVlRHMBvqDY28EHkGsoKYJN2AVVXGof5u5s22zweHodoNlve1zr_3lR8n9\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>cadorni@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (267)764-4865.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>About Berger Montague<\/strong><br \/>\n        <br \/>Berger Montague is one of the nation\u2019s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n<p align=\"justify\">\n        <strong>For more information or to discuss your rights, please contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Andrew Abramowitz<br \/>Berger Montague<br \/>(215) 875-3015<br \/>aabramowitz@bergermontague.com<\/p>\n<p align=\"justify\">Caitlin Adorni<br \/>Berger Montague<br \/>(267) 764-4865<br \/>cadorni@bergermontague.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTBmM2ZmZGMtNGQ0Yy00MWQ1LTkxOGEtNDY1Y2UxNWNkN2I0LTEwOTQ1MzMtMjAyNi0wMi0wOS1lbg==\/tiny\/Berger-Montague.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in London, Mereo is a biopharmaceutical company specializing in treatments for rare diseases. According to the complaint, while publicly raising investor expectations &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935216","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in London, Mereo is a biopharmaceutical company specializing in treatments for rare diseases. According to the complaint, while publicly raising investor expectations &hellip; Continue reading &quot;ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T13:49:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit\",\"datePublished\":\"2026-02-09T13:49:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/\",\"name\":\"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\",\"datePublished\":\"2026-02-09T13:49:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk","og_description":"PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d) on behalf of investors who purchased Mereo American Depositary Shares (ADS) during the period from June 5, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Headquartered in London, Mereo is a biopharmaceutical company specializing in treatments for rare diseases. According to the complaint, while publicly raising investor expectations &hellip; Continue reading \"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-09T13:49:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit","datePublished":"2026-02-09T13:49:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/","name":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=","datePublished":"2026-02-09T13:49:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDUxNyM3NDE0MDExIzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-mreo-investors-contact-berger-montague-about-a-mereo-biopharma-group-plc-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935216"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}